Following the established corporate strategy, the Group proactively advances the development of the vaccine product pipelines, and leverages the advantages of the mRNA technology platform to accelerate the research and development of mRNA vaccine series products through on-going technological innovation. The application for clinical trial of mRNA shingles/ herpes zoster vaccines has been submitted to the U.S. Food and Drug Administration (“FDA”) recently, marking a new advancement in the Group’s global strategy.

In preclinical animal testing, results from a third-party testing unit showed that the Group’s mRNA shingles/herpes zoster vaccine specific T-cell immunity, specific IgG antibody titers, and fluorescent antibody to membrane antigen (FAMA) titers were significantly higher than those of international commercially available recombinant subunit control vaccines.

Currently, no mRNA shingles/herpes zoster vaccine has been approved for marketing in the world. The vaccination rate of shingles/herpes zoster vaccine in the target population is only about 0.1%, leaving much room for improvement. In 2024, the global sales of GSK shingles/ herpes zoster vaccine reached approximately US$4.310 billion. According to the forecast of China Insights Industry Consultancy Limited, an industry consultant, it is expected that the market size of shingles/herpes zoster vaccines in China will reach approximately RMB20.0 billion and the global market size will reach approximately US$23.9 billion by 2030. Upon approval of the product for marketing, it will bring considerable growth to the Group’s performance. The mRNA shingles/herpes zoster vaccine is expected to reshape the market landscape due to its advantages in terms of safety and immunogenicity.

The Group is one of the enterprises that takes the lead in developing mRNA vaccine products in China, and also one of the first batch of domestic vaccine enterprises that has obtained an independent patent for mRNA technology. The Group has a mature mRNA vaccine research and development system. The Group has now smoothened the whole life cycle process such as the research, development and production of mRNA vaccines, allowing for rapid achievement of the industrialization of mRNA vaccine products after obtaining clinical approval and accelerating the commercialization process of vaccine products.